{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:39:04Z","timestamp":1791265144944,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To present a novel case that developed annular choroidal detachment after intravitreal anti-vascular endothelial growth factor antibody injection in a patient after immune checkpoint inhibitor treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 58-year-old Japanese man presented visual impairment in the right eye. Ophthalmological examination revealed macular edema in the right eye, which suggested the possibility of age-related macular degeneration. Following the intravitreal aflibercept injection, the annular choroidal detachment was observed in the injected eye. As hypotony or thick sclera was not observed, choroidal detachment seemed to have appeared due to enhanced inflammation by intravitreal injection. The patient had a history of stage IV paranasal cavity cancer and was treated with nivolumab, an immune checkpoint inhibitor. The immune response might have been enhanced due to the use of nivolumab so that intravitreal injection triggered inflammation. Three weeks after sub-tenon injection of triamcinolone acetonide, macular edema and choroidal detachment improved.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Intravitreal aflibercept injection caused annular choroidal detachment in our patient, presumably because the immune system was activated after nivolumab treatment. To the best of our knowledge, this is the first case report of annular choroidal detachment that developed after intravitreal injection in a patient with a history of nivolumab therapy. With the increasing use of immune checkpoint inhibitors in patients with various cancers, clinicians should be aware of these potentially associated immune-related adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02714-2","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:24:01Z","timestamp":1670509441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Annular choroidal detachment following intravitreal aflibercept injection in a patient with nivolumab treatment: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-0403","authenticated-orcid":false,"given":"Maho","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Kubono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Ofuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Sakakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"2714_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","volume":"28","author":"J Antoun","year":"2016","unstructured":"Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28:288\u201394.","journal-title":"Curr Opin Oncol"},{"key":"2714_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada disease-like uveitis during Nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019;10:67\u201374.","journal-title":"Case Rep Ophthalmol"},{"key":"2714_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5:694\u2013700.","journal-title":"Clin Case Rep"},{"key":"2714_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1177\/1078155219841683","volume":"25","author":"M Telfah","year":"2019","unstructured":"Telfah M, Whittaker TJ, Doolittle GC. Vision loss with pembrolizumab treatment: a report of two cases. J Oncol Pharm Pract. 2019;25:1540\u20136.","journal-title":"J Oncol Pharm Pract"},{"key":"2714_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","volume":"40","author":"M Bricout","year":"2017","unstructured":"Bricout M, Petre A, Amini-Adle M, et al. Vogt-Koyanagi-Harada-like syndrome complicating Pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40:77\u201382.","journal-title":"J Immunother"},{"key":"2714_CR6","unstructured":"Kumar N, Rana N, Bansal R. Choroidal detachment following an intravitreal injection in a patient with Vogt-Koyanagi- Harada disease. Ocul Immunol Inflamm. 2019:1\u20133 Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31664881."},{"key":"2714_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000453543","volume":"8","author":"I Elaraoud","year":"2017","unstructured":"Elaraoud I, Andreatta W, Jiang L, et al. A mystery of bilateral annular choroidal and exudative retinal detachment with no systemic involvement: is it part of Vogt-Koyanagi-Harada disease Spectrum or a new entity. Case Rep Ophthalmol. 2017;8:1\u20136.","journal-title":"Case Rep Ophthalmol"},{"key":"2714_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00417-003-0832-4","volume":"242","author":"N Yamamoto","year":"2004","unstructured":"Yamamoto N, Naito K. Annular choroidal detachment in a patient with Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol. 2004;242:355\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2714_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/ICU.0000000000000154","volume":"26","author":"HF Fine","year":"2015","unstructured":"Fine HF, Despotidis GD, Prenner JL. Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol. 2015;26:184\u20137 Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25822254.","journal-title":"Curr Opin Ophthalmol"},{"key":"2714_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","volume":"7","author":"WJ Anderson","year":"2021","unstructured":"Anderson WJ, da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retin Vitr. 2021;7:37 Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33962696.","journal-title":"Int J Retin Vitr"},{"key":"2714_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/archophthalmol.2008.530","volume":"127","author":"HF Fine","year":"2009","unstructured":"Fine HF, Spaide RF, Ryan EH, et al. Acute zonal occult outer retinopathy in patients with multiple evanescent white dot syndrome. Arch Ophthalmol (Chicago, Ill 1960). 2009;127:66\u201370 Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19139340.","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"6","key":"2714_CR12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, et al. Checkpoint Inhibitor Immune Therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063\u201378.","journal-title":"Retina"},{"key":"2714_CR13","doi-asserted-by":"crossref","unstructured":"Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients. JCI Insight. 2018;3 Available at: https:\/\/insight.jci.org\/articles\/view\/59125.","DOI":"10.1172\/jci.insight.59125"},{"key":"2714_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamaophthalmol.2018.0920","volume":"136","author":"M Thomas","year":"2018","unstructured":"Thomas M, Armenti ST, Bernadete Ayres M, Demirci H. Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol. 2018;136:553\u20136.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02714-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02714-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02714-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:27:01Z","timestamp":1670509621000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02714-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02714-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent to publish this information was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Concent for pubication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have nothing to declare about financial or non-financial competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"476"}}